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Abstract
The aim of the study was to characterize pharmacokinetics of tiotropium solution 5mg compared to powder 18mg and assess dose‐dependency of
tiotropium solution pharmacodynamics in comparison to placebo. In total 154 patients with chronic obstructive pulmonary disease (COPD) were
included in this multicenter, randomized, double‐blind within‐solution (1.25, 2.5, 5mg, and placebo), and open‐label powder 18mg, crossover study,
including 4‐week treatment periods. Primary end points were peak plasma concentration (Cmax,ss), and area under the plasma concentration–time profile
(AUC0–6h,ss), both at steady state. The pharmacodynamic response was assessed by serial spirometry (forced expiratory volume in 1 second/forced vital
capacity). Safety was evaluated as adverse events and by electrocardiogram/Holter. Tiotropiumwas rapidly absorbed with a median tmax,ss of 5–7minutes
postdosing for both devices. The gMean ratio of solution 5mg over powder 18mg was 81% (90% confidence interval, 73–89%) for Cmax,ss and 76%
(70–82%) for AUC0–6h,ss, indicating that bioequivalence was not established. Dose ordering for bronchodilation was observed. Powder 18mg and solution
5mg were most effective, providing comparable bronchodilation. All treatments were well tolerated with no apparent relation to dose or device.
Comparable bronchodilator efficacy to powder18mg at lower systemic exposure supports tiotropium solution 5mg formaintenance treatment ofCOPD.
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Inhaled long‐acting bronchodilators are established
options for the ﬁrst‐line pharmacologic management of
chronic obstructive pulmonary disease (COPD).1,2 Tio-
tropium is the ﬁrst once‐daily, long‐acting anticholinergic
bronchodilator for the maintenance therapy of patients
with COPD and is available in two formulations: an
aqueous solution (5mg) delivered via the Respimat1 Soft
MistTM Inhaler (SMI) and a dry powder (18mg) delivered
via the breath‐actuated HandiHaler1 device (both
formulations: Boehringer Ingelheim Pharma GmbH &
Co KG, Ingelheim am Rhein, Germany). Numerous
controlled trials, including either or both formulations,
have shown that tiotropium provides at least a 24‐hour
sustained improvement in airﬂow, reduced hyperinﬂation,
and shortness of breath, as well as a reduced risk of
exacerbations and associated hospitalizations, resulting in
an increased health‐related quality of life.3–10 The multi-
dose Respimat1 SMI provides a high level of satisfaction
in COPD patients due to its inhalation and handling
characteristics.11
The clinical development program of tiotropium
solution 5mg included two 4‐week, placebo‐controlled,
crossover studies, which were primarily designed to
compare tiotropium solution and powder in terms of lung
function improvement over a 12‐hour observation peri-
od.10 The prespeciﬁed pooled analysis of these two studies
revealed that tiotropium solution 5 and 10mg were
noninferior to tiotropium powder 18mg in terms of the
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Pharmacokinetics/Pharmacodynamics
primary efﬁcacy end point, trough forced expiratory
volume in 1 second (FEV1) assessed at the end of the 24‐
hour dosing interval, and a series of secondary efﬁcacy
end points (forced vital capacity [FVC], peak expiratory
ﬂow, rescue medication use). All tiotropium treatments
were well tolerated. In a subset of the study population,
urine and limited blood samples were collected for
pharmacokinetic (PK) assessments.
Both studies incorporated a double‐dummy design,
meaning that all patients inhaled from both inhalers prior to
the spirometric assessments and sampling for PK.10 While
this design is preferred in a therapeutic trial focusing on
efﬁcacy and safety, it has disadvantages for PK assessments
as early blood sampling is compromised by the additional
timerequiredand timing imprecision forpatients toproperly
inhale from two devices. Therefore, the present PK‐focused
studywas undertaken to complement the existing compara-
tive PK data in which blood sampling was limited to
predose, 10minutes, and 1 and 6 hours after tiotropium
dosing. The ﬁrst postinhalation sample at 10minutes
provided the highest mean plasma level, which may not
accurately represent the maximum plasma concentration at
steady state (Cmax,ss) because earlier time points with
potentially higher values were not assessed. The open‐label
HandiHaler1 anddouble‐blindwithinRespimat1design in
the current study allowed one inhaler precisely timed serial
blood sampling, starting as early as 2minutes following
inhalation, and allowed reliable estimation of time to
maximum plasma concentration and Cmax,ss.
The primary objective of this open‐label, randomized,
double‐blind within solution (tiotropium 1.25, 2.5, 5mg
and placebo), 5‐way crossover study including 4‐week
treatment periods, was to characterize the PK of
tiotropium solution 5mg in comparison to tiotropium
powder 18mg. Secondary objectives were to characterize
the PK of tiotropium solution 1.25 and 2.5mg, additional
PK end points and to assess the dose dependency of
pharmacodynamics of tiotropium solution (spirometry)
compared to placebo.
Methods
Study Design
This study (#205.458 [sponsor’s protocol number],
clinicaltrials.gov: NCT01222533) was designed as a
multicenter, placebo‐controlled, randomized, double‐
blind (within Respimat1 SMI), 5‐way, crossover trial
with 4‐week treatment periods of placebo and once‐daily
tiotropium doses of 1.25, 2.5, and 5mg (two puffs of
0.625, 1.25, and 2.5mg, respectively) as aqueous solution
for inhalation via the Respimat1 SMI and open‐label
tiotropium 18mg as dry powder for inhalation via
HandiHaler1. All doses were administered in the morning
between 7:00 and 10:00 am. There was no washout period
between the 4‐week treatment periods, but 4 weeks’
treatment is sufﬁcient to reach PK and pharmacodynamic
(PD) steady state before the test days.12,13 Compliance
with medication use was recorded.
Following an initial screening visit to assess eligibility
and a 1‐week run‐in period, eligible patients were assigned
to a treatment sequence for evaluation of PK after 26 days
and PD after 28 days at the end of each of the ﬁve treatment
periods.Medications for the routinemanagement of COPD
were permitted throughout the study period, provided that
dosages had been stabilized for at least 6 weeks prior to
screening. These included oral corticosteroids at low doses
(10mg prednisolone daily or equivalent), inhaled
corticosteroids, mucolytic agents (not containing broncho-
dilators), antihistamines, antileukotrienes (unless pre-
scribed for asthma or excluded allergic conditions), and
twice‐daily inhaled long‐acting b2‐agonists (LABAs),
such as formoterol or salmeterol. LABAs were withdrawn
at least 24 hours prior to each PK test day and at least
48 hours prior to pulmonary function test (PFT) days.
Open‐label salbutamol was provided and patients were
instructed to use it as needed for acute symptom relief and
to withdraw its use at least 8 hours prior to any clinic test
day. Short‐acting anticholinergics were permitted during
the screening and run‐in periods, and withdrawn at least
8 hours prior to PFTs. Patients discontinued once‐daily
LABA (indacaterol), long‐acting anticholinergics, oral
b2‐adrenergic agonists, and b‐blockers at least 2 weeks
prior to the screening visit in order to have at least a 3‐week
washout period prior to randomization. Medications to
control acute exacerbations were allowed during random-
ized treatment according to medical need.
Prior to the start of the study, the clinical trial protocol
and other relevant study documentation were reviewed by
the Independent Ethics Committee of the participating
centers (University Hospital Gent [central committee for
Belgian sites]; De Videnskabsetiske Komitéer for Region
Hovedstaden, Hillerød, Denmark [central committee for
Danish sites]; HUS Medisiininen Eettinen toimikunta,
Helsinki, Finland; Ethikkommission der Medizinischen
Hochschule, Hannover, Germany; METC Atrium‐Orbis‐
Zuyd, Heerlen, the Netherlands [central committee for
Dutch sites]). The studywas conducted in accordance with
the Declaration of Helsinki (1996). Written informed
consent was obtained prior to any study‐related procedure.
Patients
Patients eligible for inclusion were men or women aged
40 years, current, or ex‐smokers with a smoking history
of 10 pack‐years, and diagnosed with COPD2 (post-
bronchodilator FEV1 <80% of predicted
14 and postbron-
chodilator FEV1/FVC ratio <70%). The main exclusion
criteria included signiﬁcant diseases other than COPD,
diagnosis of asthma, elevated blood eosinophil count
(600mm3), recent history (i.e., 6 months or less) of
myocardial infarction, unstable or life‐threatening cardiac
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arrhythmia requiring intervention or change in drug
therapy during the past year, hospitalization for cardiac
failure during the past year, malignancy requiring
resection, radiation therapy, or chemotherapy within the
last 5 years. Patients with a respiratory infection or COPD
exacerbation in the 6 weeks prior to screening or during
the run‐in period were allowed to be randomized 6 weeks
following recovery from the event.
Study Assessments
On day 26 of each treatment period, blood samples were
collected5minutes beforedosingandduring a6‐hour period
at 2, 5, 7, 9, 12, 15, 20, 30, 40, 60minutes, and 2, 4, and
6 hours post dosing. In addition, urine for the assessment of
tiotropium excretion was collected 1 to 0 hours (predos-
ing), and 0–2 and 2–6 hours postdosing. Tiotropium
concentrations were determined by a validated assay using
high‐performance liquidchromatographycoupled to tandem
mass spectrometry (Nuvisan GmbH, Neu‐Ulm, Germany).
Compared to the assay previously used,8 the reﬁned assay
had a lower limit of quantiﬁcation of 1.0 pg/mL.
PFTs were conducted according to the American
Thoracic Society criteria.15 At screening, prebronchodi-
lator and qualifying postbronchodilator spirometric tests
(FEV1, FVC) were performed (45minutes after inhalation
of four puffs of salbutamol 100mg metered‐dose inhaler).
After completion of the run‐in period, the study baseline
FEV1 and FVC were determined before inhalation of the
ﬁrst dose of studymedication. On day 28 of each treatment
period, 2 days after the PK test day, serial 6‐hour
spirometry was conducted at 10minutes before and at 30
and 60minutes, and 2, 3, 4, 5, and 6 hours after inhalation
of study medication. Safety evaluations included adverse
event (AE) recording throughout the study and ECG/
Holter monitoring on the 6‐hour PFT days.
Statistical Analyses
The primary end points for PK evaluation of tiotropium
solution 5mg versus tiotropium powder 18mg at PK/PD
steady state were Cmax,ss and the area under the plasma
concentration–time curve proﬁle from 0 to 6 hours at
steady state (AUC0–6h,ss). These primary PK end points
were expected to follow a log‐normal distribution,
whereas the FEV1‐ and FVC‐based secondary efﬁcacy
end points (AUC0–6h, trough and AUC0–3h) were expected
to follow a normal distribution. The average FEV1 and
FVC (AUC0–3h, AUC0–6h) were calculated as the AUC
from 0 to 3 or 6 hours, respectively, using the trapezoidal
rule divided by the corresponding duration (i.e., 3 or
6 hours) to give the result in liters. The predose or trough
FEV1 (or FVC) value was assigned to zero time and
deﬁned as the measurement before administration of the
last once‐daily dose of study drug at the end of each 4‐
week treatment period. Based upon design and distribu-
tional considerations, analysis of variance (ANOVA)
suitable for crossover trials was employed, using a mixed‐
effects model. The ANOVA model accounted for the
following sources of variation: “sequence,” “patients
within sequences,” “period,” and “treatment.” “Patients
within sequences”was considered random, while the other
effects were ﬁxed.
Cmax,ss and AUC0–6h,ss were log transformed prior to
ﬁtting the ANOVA model. The difference between the
expected means for log(T)–log(R) (i.e., test treatment
tiotropium solution 5mg, reference treatment tiotropium
powder 18mg) was estimated by the difference in the
corresponding least square means (point estimate) and
2‐sided 90% conﬁdence intervals (CIs) were computed.
These quantities were back transformed to the original
scale to give the geometric mean (gMean) and interval
estimates for the median intrapatient ratio between the
response under test (tiotropium solution 5mg) and
response under reference (tiotropium powder 18mg).
Bioequivalence of the two inhaled products was
assumed if the 90% CIs for each of the ratios of the
gMeans of Cmax,ss and AUC0–6h,ss of the test (tiotropium
solution 5mg) and reference product (tiotropium powder
18mg) were contained in the predeﬁned acceptance
interval of 80–125%.16
The spirometric efﬁcacy of tiotropium solution 2.5
or 5mg was established by a 2‐sided test at a¼ 0.05. A
1‐sided test at a¼ 0.025 was performed to see if
tiotropium solution 1.25mg was an ineffective dose
compared to placebo. In order for tiotropium solution
1.25mg to be declared an ineffective dose compared to
placebo, the 95% CI for the treatment difference had to lie
entirely below the prespeciﬁed limit of 0.1 L.
The PK end point analyses were based on the PK set,
while analyses of the efﬁcacy (spirometry) end points were
performed for the full analysis set (FAS) (i.e., patients who
had received at least one dose of study medication and for
whom ontreatment data for at least one efﬁcacy end point
was available) and the per‐protocol set (FAS and did not
experience a relevant important protocol violation). Evalu-
ation of safety end points (AEs, including patients who
received at least one dose of study medication, and ECG/
Holter) were summarized descriptively for the treated set.
In order to determine whether tiotropium solution
1.25mg was an ineffective dose compared to placebo, 120
completed patients were required, assuming a type I error
rate (a) of 0.025 (1‐sided), 90% power, a standard
deviation of the within‐patient treatment differences of
0.167 L,3,8,10 and a treatment difference of 0.1 L compared
to placebo. After accounting for a dropout rate of 15%, 142
patients were planned to be randomized.
Results
A total of 154 patients were randomized to treatment.
Table 1 provides the demographics and baseline
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characteristics at screening for the patients included in the
efﬁcacy and safety analyses. The majority of patients were
male (76%), current smokers (64%) with a mean
prebronchodilator FEV1 of 1.44 L (48% of predicted
normal), and a mean COPD duration of 9 years;
comparable data were seen for the subgroup included in
the PK assessments. Patient disposition and the number of
patients randomized to each 4‐week treatment group are
provided in Figure 1; 140 patients (91%) completed the
study.
Pharmacokinetics
The gMean plasma concentration–time proﬁles following
26 days of once‐daily dosing with the three tiotropium
solution doses (1.25, 2.5, or 5mg) or tiotropium powder
18mg are shown in Figure 2A. Following inhalation with
tiotropium solution, there was a dose‐dependent increase
in tiotropium plasma exposure as determined by Cmax,ss
(Figure 2B), and the amount of drug eliminated in Ae0–6,ss
and AUC0–1,ss values (Table 2). The PK parameters
obtained with both tiotropium formulations are summa-
rized by treatment group in Table 2.
Following inhalation from either device, tiotropium
was rapidly absorbed with similar tmax,ss values for all
treatments ranging between 5 and 7minutes postdosing.
The Cmax,ss estimation is reliable because quantiﬁable
tiotropium plasma levels were obtained from at least at one
time point before tmax,ss was reached. FromCmax,ss, plasma
concentrations declined rapidly for 30minutes followed
by a more gradual decline until 6 hours postdosing. The
shape of the tiotropium plasma proﬁle was similar
following inhalation from both devices. Mean plasma
concentrations were (slightly) lower with tiotropium
solution 5mg compared with tiotropium powder 18mg
(Figure 2A).
Bioequivalence Testing of Solution 5mg Versus Powder
18mg
Bioequivalence was not observed based on a comparison
of the Cmax,ss and AUC0–6,ss values. The corresponding
gMean ratio for the Cmax,ss values of 10.5 pg/mL (5mg)
and 12.9 pg/mL (18mg) was 81% and the 90% CI
(73–89%) was below the prespeciﬁed acceptance interval
of 80–125%. The gMean AUC0–6h,ss values were
22.1 pg · h/mL following tiotropium solution 5mg and
28.4 pg · h/mL following tiotropium powder 18mg. The
corresponding ratio of the AUC0–6h,ss values was 76%
(90% CI: 70–82%) and again, the 90% CI was below the
prespeciﬁed acceptance interval of 80–125%, indicating
that bioequivalence was not established. The difference of
6.3 pg · h/mL (22%) found between both drug products in
terms of AUC0–6h,ss was supported by Ae0–6h,ss. In the
time interval 0–6 hours postdose, the amount of renally
excreted tiotropium was 26% lower following the
administration of tiotropium solution 5mg compared
with tiotropium powder 18mg (Table 2).
Evaluation of Dose Proportionality (Solution Doses
1.25, 2.5, or 5mg)
The Cmax,ss and the Ae0–6h,ss values increased in
proportion to the inhaled tiotropium solution dose. Based
on the plasma levels reliably measured until 1 hour
postinhalation (AUC0–1h,ss), exposure to tiotropium
Table 1. Demographics and Characteristics at Screening and
Randomization Visits
Variablesa Treated set (N¼ 154)
Screening visit
Male (%) 76.0
Age (years) 63.1 (7.8)
Smoking status:
Ex‐smoker (%) 36.4
Current smoker (%) 63.6
Smoking history (pack‐years) 47.5 (21.5)
FEV1 prebronchodilator (L) 1.4 (0.5)
Percent predicted normal 48.1 (14.3)
FVC prebronchodilator (L) 3.3 (1.0)
FEV1/FVC prebronchodilator (%) 44.5 (10.9)
FEV1 postbronchodilator (L) 1.6 (0.6)
Percent predicted normal 54.4 (14.5)
FVC postbronchodilator (L) 3.6 (1.0)
FEV1/FVC postbronchodilator (%) 45.6 (11.0)
Reversibility FEV1 (L) 0.2 (0.1)
Reversibility FEV1 (%) 14.7 (10.9)
COPD severity according to GOLD (%)
Moderate (50 to <80%) 63.0
Severe (30 to <50%) 31.2
Very severe (<30%) 5.8
Prestudy medication for COPD, n (%)
Inhaled short‐acting anticholinergics 10 (6.5)
Inhaled long‐acting anticholinergics 79 (51.3)
Inhaled short‐acting b2‐adrenergics 59 (38.3)
Inhaled long‐acting b2‐adrenergics 90 (58.4)
Inhaled corticosteroids 81 (52.6)
Oral corticosteroids 2 (1.3)
Theophylline 3 (1.9)
Randomization visit (study baseline)
FEV1 (L) 1.4 (0.6)
FEV1 (% predicted normal) 47.4 (14.4)
COPD medication during randomized study period, n (%)
Inhaled long‐acting b2‐adrenergics 90 (58.4)
Inhaled corticosteroids 80 (51.9)
Oral corticosteroids 1 (0.6)
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for
Chronic Obstructive Lung Disease.
Medications permitted throughout the entire study period included oral
corticosteroids at minimal doses (20mg), orally inhaled corticosteroids,
mucolytic agents (not containing bronchodilators), antihistamines, antileuko-
trienes, and leukotriene receptor antagonists (unless prescribed for asthma
or excluded allergic conditions) and orally inhaled twice daily long‐acting b2‐
adrenergic agents (formoterol or salmeterol).
aData are mean (SD) unless otherwise stated.
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increased in a dose–proportional manner in line with the
Cmax,ss and Ae0–6,ss values.
Spirometry
The FEV1 time–response curves after inhalation of three
doses (1.25, 2.5, and 5mg) of tiotropium solution and
tiotropium powder 18mg are shown in Figure 3; end
points derived from the 6‐hour proﬁles are presented in
Table 3.
Tiotropium solution doses 1.25, 2.5, and 5mg and
tiotropium powder 18mg provided signiﬁcantly
(P< .0001) greater bronchodilation compared to placebo
in all spirometric end points. This hypothesis was only
predeﬁned for the doses 2.5 and 5mg. It was hypothesized
that the 1.25‐mg dose would be no more effective than
placebo. This would have been assumed if the upper limit
of the 95% CI for the difference (1.25mg to placebo) was
below the predeﬁned limit of 0.1 L, which was not the
case. However, effects with the lowest dose of tiotropium
solution (1.25mg) were statistically inferior to the 18‐mg
dose of tiotropium powder in all FEV1‐based end points.
Considering FEV1 AUC0–6h and FEV1 AUC0–3h, the 2.5‐
and 5‐mg dose of tiotropium solution were the most
effective and comparable with tiotropium powder 18mg.
However, within the ﬁrst hour postdosing, tiotropium
solution 2.5mg provided fewer bronchodilatory effects
compared with both tiotropium solution 5mg and
tiotropium powder 18mg, while tiotropium solution
5mg and tiotropium powder 18mg were similar. In
addition, we observed a statistically signiﬁcant higher
trough FEV1 following treatment with tiotropium powder
18mg compared with tiotropium solution 2.5mg, but not
with tiotropium powder 18mg compared with tiotropium
solution 5mg (Table 3).
Improvements observed in the 6‐hour FVC time‐
response curves mirror the FEV1 ﬁndings. Irrespective of
the inhaler, signiﬁcantly higher responses in FVC were
observed with all four tiotropium treatments compared to
placebo, with the most pronounced and similar broncho-
dilatory effects to tiotropium powder 18mg seen
following the 2.5‐ and 5‐mg doses of tiotropium solution.
Again, a numerically lower response in FVC was found
following the 2.5‐mg dose at the end of the 24‐hour
dosing interval (trough) and within the ﬁrst hour
postdosing.
Individual trough FEV1 and FEV1 AUC0–3h values
were compared with the corresponding trough tiotropium
plasma concentrations (Cpre,ss) and the maximum plasma
concentrations at steady state (Cmax,ss), respectively
(Supplementary Figures 1 and 2). No correlation was
found between the response in FEV1 and the tiotropium
plasma concentration.
Figure 1. Flow diagram, design, and patient disposition. A total of 210 patients were initially enrolled and screened. Following a 1‐week run‐in period,
154 patients were randomized to five treatment groups, for a 4‐week period. The number of patients in each treatment group that comprised the
treatment set (TS) and the pharmacokinetic set (PS) at randomization and study end is indicated. The number of patients in each treatment group who
prematurely discontinued treatment, reported any adverse event (AE) or serious AE is also indicated in the figure. The result showed that tiotropium
delivered either as a powder or solution was well tolerated.
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Safety
Six patients (3.9%) prematurely discontinued study
medication due to an AE, ﬁve of whom subsequently
withdrew from the study and one continued with the next
two treatment periods and completed the study. AEs
leading to study discontinuation occurred in two patients
on placebo (worsening of COPD, development of hernia)
and one patient on tiotropium solution 5mg (worsening of
COPD), one patient on tiotropium solution 1.25mg
(worsening of baseline condition esophageal reﬂux),
and two patients on tiotropium powder 18mg (worsening
of COPD and pneumonia). The frequency of AEs was
balanced between the tiotropium treatment periods and
similar to the placebo period with the exception of
complaints of dyspnea and worsening of COPD, which
were more frequently reported during the placebo period.
In total, 10 patients experienced a serious AE. Of these,
three in the placebo period (one with a hemorrhoidal
Figure 2. Clinical study. (A)Geometricmean tiotropium plasma concentration–time profile followingmultiple inhalations as solution or as powder. (B)
Comparison of maximum tiotropium plasma concentrations at steady state (Cmax,ss) by dose and device (solution versus powder). On day 26 of each
treatment period, blood samples were collected 5minutes before dosing and during a 6‐hour period at 2, 5, 7, 9, 12, 15, 20, 30, 40, 60minutes, and 2, 4,
and 6 hours postdosing. Tiotropium concentrations were determined by a validated assay using high‐performance liquid chromatography coupled to
tandem mass spectrometry. (A) Mean plasma concentrations were (slightly) lower with tiotropium solution 5mg compared with tiotropium powder
18mg. (B) There was a dose‐dependent increase in tiotropium plasma exposure as determined by Cmax.
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hemorrhage, two with an exacerbation of COPD), three
while on tiotropium solution 5mg (colitis ischemic,
pancreatitis, renal tubular necrosis/azotemia), two on
tiotropium solution 1.25mg (cerebrovascular accident/
spinal column stenosis, prostate cancer), and two on
tiotropium powder 18mg (exacerbation of COPD,
pneumonia). None of these events was considered related
to study medication. There was no apparent treatment‐
related effect or pattern in the ECG/Holter assessments,
which will be separately reported in the context of a
broader analysis including several studies.
Discussion
Tiotropium powder 18mg and tiotropium solution 5mg
are different formulations for the same active ingredient.
While developed and proﬁled in standalone, full
programs, the delivered dose of tiotropium solution was
Table 2. PK Parameters by Treatment Group
Variable
Tiotropium solution Tiotropium powder
1.25mg 2.5mg 5.0mg 18.0mg
n gMean gCV (%) n gMean gCV (%) n gMean gCV (%) n gMean gCV (%)
Cmax,ss (pg/mL) 104 2.8 53.0 110 5.1 61.8 113 10.5 66.4 113 12.9 64.6
Cmax,ss,norm (pg/mL/mg) 104 2.3 53.0 110 2.0 61.8 113 2.1 66.4 113 0.7 64.6
AUC0–6h,ss (pg · h/mL) 22 10.0 25.3 76 12.8 29.9 107 22.1 47.8 113 28.4 52.4
AUC0–6h,ss,norm (pg · h/mL/mg) 22 8.0 25.3 76 5.1 29.9 107 4.4 47.8 113 1.6 52.4
AUC0–1h,ss (pg · h/mL) 61 2.1 32.3 97 3.2 44.4 112 6.1 58.3 113 7.8 54.9
AUC0–1h,ss,norm (pg · h/mL/mg) 61 1.7 32.3 97 1.3 44.4 112 1.2 58.3 113 0.4 54.9
Ae0–6h,ss (ng) 108 88.7 68.0 110 177 68.0 107 387 65.9 109 522 53.8
f0–6h,ss (%) 108 7.09 68.0 110 7.1 68.0 107 7.8 65.9 109 2.9 53.8
tmax,ss (h)
a 104 0.100 0.0330–2.00 110 0.0830 0.0330–6.00 113 0.117 0.0330–0.333 113 0.117 0.0330–1.00
Ae0–6h,ss, amount of drug excreted in urine from 0 to 6 hours at steady state; AUC0–1h,ss, area under the plasma concentration–time profile from 0 to 1 hour at
steady state; AUC0–1h,ss,norm, normalized area under the plasma concentration–time profile from 0 to 6 hours at steady state; AUC0–6h,ss, area under the plasma
concentration–time profile from 0 to 6 hours at steady state; AUC0–6h,ss,norm, normalized area under the plasma concentration–time profile from 0 to 6 hours at
steady state; Cmax,ss, peak plasma concentration at steady state; Cmax,ss,norm, normalized peak plasma concentration at steady state; f0–6h,ss, fraction of the delivered
dose excreted in urine from 0 to 6 hours at steady state; gCV, geometric coefficient of variation; gMean, geometric mean; tmax,ss, time to Cmax at steady state.
aMedian and range.
Figure 3. Adjustedmean FEV1 over 6 hours at day 28. On day 28 of each treatment period, 2 days after the pharmacokinetic (PK) test day, serial 6‐hour
spirometry was conducted at 10minutes before and at 30 and 60minutes, and 2, 3, 4, 5, and 6 hours after inhalation of study medication. Tiotropium
solution doses 1.25, 2.5, and 5mg and tiotropium powder 18mg provided significantly (P< .0001) greater bronchodilation compared to placebo in all
spirometric end points.Within the first hour postdosing, tiotropium solution 2.5mg provided less bronchodilatory effects compared with both solution
5mg and powder 18mg, while solution 5mg and powder 18mg were similar. FEV1, forced expiratory volume in 1 second.
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adjusted because of the high device efﬁciency to a value
below the nominal dose of tiotropium powder to achieve
comparability in efﬁcacy and systemic exposure. For
inhaled medications, systemic availability and exposure
is typically discussed in the context of safety, whereas it is
not considered predictive for efﬁcacy. Many inhaled
medications, among them tiotropium,17 are absorbed
rapidly from the lungs, so that assessment of tmax and
Cmax is critical and requires precise and early sampling.
Earlier efﬁcacy and PK studies8,18 had shown numerically
higher or similar exposure to tiotropium following
treatment with tiotropium solution 5mg compared with
tiotropium powder 18mg. Taking up a numerical
imbalance in mortality of tiotropium solution compared
to placebo,19 recent systematic reviews and meta‐
analyses of randomized trials, including 1‐year stud-
ies,3,4,8,9 have reported a potential association between
the use of tiotropium solution 5mg and an increased risk
of mortality in COPD patients.20–22 Higher peak and
overall tiotropium exposure following inhalation from the
Respimat1 SMI has been suggested to be causally related
to this observation.22 For this reason, optimized PK and
efﬁcacy comparison of the 2 tiotropium formulations is
very important. The crossover and open‐label design
(instead of double‐dummy) for comparison across
formulations is an essential feature of this study allowing
precise timing as early as 2minutes following inhalation.
The study included an elderly COPD patient population
and allowed typical co‐medication. Since both tiotropium
formulations are indicated for the maintenance therapy in
COPD, the bioequivalence primary end points were
determined at PK steady state, the most relevant time
point. After chronic once‐daily inhalation of tiotropium
powder by COPD patients, PK steady state is reached
after 2–3 weeks with no accumulation thereafter.12 From
this perspective, the study is representative for clinical use
and deﬁnes a high standard for investigating inhaled
medications.
Table 3. Clinical Study: FEV1 Results by Treatment Group
Treatment group
Placebo
(n¼ 143)
Solution 1.25mg
(n¼ 143)
Solution 2.5mg
(n¼ 144)
Solution 5mg
(n¼ 143)
Powder 18mgb
(n¼ 142)
Day 29 FEV1 AUC0–6h (mL)
Adjusted mean (SE) 1,371 (46) 1,535 (46) 1,556 (46) 1,562 (46) 1,567 (46)
Comparison versus placeboa
Adjusted mean (SE) 165 (12) 185 (12) 191 (12) 196 (12)
95% CI 141, 189 161, 209 167, 216 172, 220
P‐value <.0001a <.0001 <.0001 <.0001
Comparison versus powder 18mg
Adjusted mean (SE) 31 (12) 11 (12) 5 (12)
95% CI 55, 7 35, 13 29, 19
Trough FEV1 (mL)
Adjusted mean (SE) 1,345 (45) 1,432 (45) 1,446 (45) 1,466 (45) 1,473 (45)
Comparison versus placeboa
Adjusted mean (SE) 87 (14) 101 (14) 121 (14) 128 (14)
95% CI 60, 114 74, 128 94, 148 101, 155
P‐value <.0001a <.0001 <.0001 <.0001
Comparison versus powder 18mg
Adjusted mean (SE) 41 (14) 27 (14) 7 (14)
95% CI 68, 14 55, 0 34, 20
Day 29 FEV1 AUC0–3h (mL)
Adjusted mean (SE) 1,366 (46) 1,521 (46) 1,546 (46) 1,553 (46) 1,558 (46)
Comparison versus placeboa
Adjusted mean (SE) 155 (13) 180 (13) 187 (13) 191 (13)
95% CI 130, 180 155, 205 162, 211 167, 216
P‐value <.0001a <.0001 <.0001 <.0001
Comparison versus powder 18mg
Adjusted mean (SE) 36 (13) 11 (13) 5 (13)
95% CI 61, 12 36, 13 29, 20
AUC0–3h, area under the curve from 0 to 3 hours; AUC0–6h, area under the curve from 0 to 6 hours; CI, confidence interval; FEV1, forced expiratory volume in
1 second; SE, standard error.
aSuperiority tests for tiotropium solution 1.25mg versus placebo were not predefined; in order for tiotropium solution 1.25mg to be declared an ineffective dose
compared to placebo, the 95% CI for the treatment difference had to lie entirely below the prespecified limit of 0.1 L.
bTiotropium powder 18mg was not blinded.
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The key result of this extensive comparative PK study
in patients with COPD demonstrated a lower systemic
exposure and availability of tiotropium following treat-
ment with tiotropium solution 5mg compared with
tiotropium powder 18mg (gMean for Cmax,ss 19% lower
and for AUC0–6h,ss 24% lower). Although we observed
widely overlapping ranges of individual plasma levels,
formal testing revealed that bioequivalence was not
established. In line with the ratio of 76% for solution
versus powder in terms of plasma AUC0–6h,ss, the amount
of renally excreted tiotropium over the 6‐hour postdosing
period was 26% lower for tiotropium solution 5mg
compared with tiotropium powder 18mg. Thus, the renal
excretion based on a 6‐hour postdose urine
collection period appeared to be a reliable indicator of
plasma AUC0–6h,ss values.
The dose‐normalized total exposure based on
AUC0–6h,ss for the 1.25‐mg dose was higher than that
of other dose groups. However, this value may not be
representative because tiotropium plasma concentrations
were below the limit of quantiﬁcation by 1 hour postdose
for a majority of patients and hence were not included in
estimating the average. Systemic exposure to tiotropium
solution 1.25–5mg increased in a dose–proportional
manner based on Cmax,ss, Ae0–6h,ss, and AUC0–1h,ss
values.
From these results, it is evident that the chosen
design was successful in capturing the actual peak
plasma concentration as quantiﬁable tiotropium plasma
levels were obtained at least one time point before
reaching tmax,ss. Due to the early and serial sampling
postdosing, a reliable estimate of peak exposure (Cmax,ss)
was achieved in this large COPDpopulation. Furthermore,
the complete plasma concentration–time proﬁle was
adequately described during the 6‐hour observation
period; the reﬁned assay with a low limit of quantiﬁcation
(1.0 pg/mL) allowed quantifying of tiotropium in plasma
in the majority of patients up to 6 hours postdosing with
solution 2.5–5mg and powder 18mg.
As already mentioned, previously conducted PK
studies had shown similar18 or numerically higher8
exposure with tiotropium solution 5mg compared with
tiotropium powder 18mg. When discussing the differ-
ences in results, it is important to take aspects of the study
design into account. In the present study, the focus on PK
allowed precise timing, early and serial blood sampling
over a 6‐hour period, while the previously conducted
studies that focused on bronchodilator efﬁcacy had only
10‐minute sampling and less precise timing with solution
inhaled after powder. The published result of the
prespeciﬁed pooled analysis of two studies8 reported a
numerically higher gMean value of the plasma concentra-
tion at 10minutes postdosing for tiotropium solution 5mg
compared with tiotropium powder 18mg (11.5 and
8.49 pg/mL, respectively). The closest comparison using
the current dataset is by selecting the gMean 9‐minute
postdose values, which showed a numerically lower
gMean value for tiotropium solution 5mg compared with
tiotropium powder 18mg (9.14 vs. 11.2 pg/mL, respec-
tively). The difference between study sets may be due to
differences in the study populations or study design
differences, although an overall difference of 2–3 pg/mL
in gMean tiotropium plasma levels following inhalation
can be considered small. Evaluation of the intra‐individual
comparison between devices/formulations did not suggest
a relevant difference in bioavailability. Another PK
investigation in Japanese COPD patients showed compa-
rable systemic exposure with the two tiotropium
formulations.18
The apparent small difference in systemic exposure
based on plasma and urine levels between tiotropium
solution 5mg and tiotropium powder 18mg in our study is
not reﬂected in the bronchodilator efﬁcacy. Comparable
spirometric improvements were observed for both
approved tiotropium formulations. The study was not
designed and powered for comparisons between each
tiotropium solution dose (1.25–5mg) and tiotropium
powder 18mg. Tiotropium solution 5mg was shown to
be the most comparable dose to tiotropium powder 18mg
in all FEV1 and FVC‐based end points. Tiotropium
solution 2.5mg showed comparable bronchodilator efﬁ-
cacy in FEV1 and FVC to tiotropium powder 18mg from 1
to 6 hours postdosing, while improvements were lower
than the comparator in the ﬁrst 60minutes postinhalation.
The mean FEV1 at the end of the 24‐hour dosing interval
(trough value) for tiotropium solution 2.5mg was again
signiﬁcantly lower than the comparator (trough FVC
numerically lower). Previously reported studies3,8 have
shown non‐signiﬁcant differences between 5 and 10mg
in terms of pulmonary effects, which may indicate
that tiotropium solution 5mg is at the dose–response
plateau.
All active treatments were well tolerated, similar to
placebo and consistent with previous trials with similar
treatment periods.8,18 There were no new safety signals
and no fatal events. The current extensive study conﬁrms
in a large COPD population the results from the earlier
comparative PK studies and does not indicate any relevant
difference in absorption rate and extent of exposure
between tiotropium solution 5mg and tiotropium powder
18mg. Therefore, the suggested causal relation of a
mortality imbalance to differential tiotropium exposure is
unsubstantiated.
In conclusion, the current extensive comparative PK
and bronchodilator efﬁcacy study in patients with COPD
demonstrated a lower exposure but similar bronchodilator
efﬁcacy of once‐daily tiotropium solution 5mg compared
with tiotropium powder 18mg and supports the use of both
approved tiotropium formulations for the maintenance
treatment of patients with COPD.
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